Get the Stockscreener App
152.98
0.68%
-1.04
Pre-market:
155.43
2.45
+1.60%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $152.98, with a volume of 607.81K.
It is down -0.68% in the last 24 hours and down -1.30% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$154.02
Open:
$153.05
24h Volume:
607.81K
Relative Volume:
0.78
Market Cap:
$17.07B
Revenue:
$9.54B
Net Income/Loss:
$841.00M
P/E Ratio:
20.56
EPS:
7.44
Net Cash Flow:
$1.02B
1W Performance:
-0.43%
1M Performance:
-1.30%
6M Performance:
+6.16%
1Y Performance:
+13.07%
1-Day Range:
$150.41
$153.12
1-Week Range:
$150.41
$155.45
52-Week Range:
$123.04
$165.32
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
152.98 | 17.07B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
556.99 | 213.05B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
237.62 | 171.63B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
143.43 | 40.54B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.96 | 35.93B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
418.63 | 34.28B | 3.84B | 866.24M | 792.60M | 10.37 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics (NYSE:DGX) Downgraded by StockNews.com to "Hold" - MarketBeat
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Clean Yield Group Purchases 3,983 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Relationship Genetic Tests Market Report 2024, Featuring - GlobeNewswire
Relationship Genetic Tests Market Report 2024, Featuring Profiles of Laboratory Corporation of America, Quest Diagnostics, Cleveland Clinic, Myriad Genetics, Invitae and More - Yahoo Finance
Zacks Research Has Bullish Outlook for DGX FY2025 Earnings - MarketBeat
Ex-Dividend Reminder: Universal Corp, Shoe Carnival and Quest Diagnostics - Nasdaq
Alzheimer's Disease Diagnostics Research Report 2024-2034: Global Market to Reach $27.87 Billion - GlobeNewswire Inc.
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics Employee Shares How Music Career Led to Healthcare Logistics Success - StockTitan
Quest Diagnostics Strengthens Leadership Team with Chief Quality Officer Appointment - StockTitan
Nordea Investment Management AB Sells 13,456 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics (NYSE:DGX) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Quest Diagnostics Inc. stock rises Monday, still underperforms market - MarketWatch
Leerink Partners Upgrades Quest Diagnostics (DGX) - MSN
Quest Diagnostics (NYSE:DGX) Upgraded to "Outperform" at Leerink Partners - MarketBeat
Quest Diagnostics upgraded by Leerink Partners with a new price target - Quantisnow
Quest Diagnostics (NYSE:DGX) shareholders have earned a 9.4% CAGR over the last five years - Simply Wall St
Quest Diagnostics Inc. stock rises Friday, still underperforms market - MarketWatch
Why Quest Diagnostics (DGX) is Poised to Beat Earnings Estimates Again - Yahoo Finance
OhioHealth outsourcing some lab work to Quest Diagnostics - The Business Journals
Quest Diagnostics to Release Fourth Quarter and Full Year 2024 Financial Results on January 30, 2025 - Longview News-Journal
Quest Diagnostics to Report Q4 and Full Year 2024 Results on January 30 Before Market Open - StockTitan
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Should You Hold Quest Diagnostics Stock in Your Portfolio Now? - MSN
How Is Quest Diagnostics' Stock Performance Compared to Other Diagnostics & Research Stocks? - MSN
How Is The Market Feeling About Quest Diagnostics? - Benzinga
Short Interest in Quest Diagnostics Incorporated (NYSE:DGX) Declines By 6.4% - MarketBeat
JPMorgan Chase & Co. Sells 18,505 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Lobbying Update: QUEST DIAGNOSTICS INCORPORATED just disclosed $80,000 of lobbying spending - Nasdaq
Quest Diagnostics Incorporated (NYSE:DGX) Receives $169.15 Average PT from Brokerages - MarketBeat
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Quest Diagnostics Inc. stock rises Tuesday, still underperforms market - MarketWatch
Quest Diagnostics Unveils Ambitious ESG Goals in 2023 Corporate Responsibility Report - StockTitan
Franklin Resources Inc. Acquires 17,240 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Principal Financial Group Inc. Grows Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Tidal Investments LLC Has $679,000 Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
StockNews.com Upgrades Quest Diagnostics (NYSE:DGX) to "Buy" - MarketBeat
Quest Diagnostics (NYSE:DGX) Stock Quotes, Forecast and News Summary - Benzinga
Quest Diagnostics to Speak at the 7th Annual Evercore HealthCONx Conference - The Eastern Progress Online
August 2025 Options Now Available For Quest Diagnostics (DGX) - Nasdaq
Quest Diagnostics Launches Health Coaching on questhealth.com to Help Individuals Take Control of Their Health - The Eastern Progress Online
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Yahoo Finance
Mainz Biomed N.V. Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Marketscreener.com
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Sanctuary Advisors LLC Raises Stock Position in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):